Beth C. Seidenberg - 29 May 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: Director, 10%+ Owner
Signature: By: /s/ Ryan Jones, as Attorney-in-Fact
Issuer symbol: KYTX
Transactions as of: 29 May 2025
Net transactions value: $0
Form type: 4
Filing time: 02 Jun 2025, 18:35:50 UTC
Previous filing: 23 May 2025
Next filing: 10 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SEIDENBERG BETH C	Director, 10%+ Owner	C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE	By: /s/ Ryan Jones, as Attorney-in-Fact	02 Jun 2025	0001184592

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYTX	Common Stock	Award	$0	+16,634		$0.000000	16,634	29 May 2025	Direct	F1
holding	KYTX	Common Stock						3,787,940	29 May 2025	See Footnote	F3
holding	KYTX	Common Stock						735,984	29 May 2025	See Footnote	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYTX	Stock Option (right to buy)	Award	$0	+65,351		$0.000000	65,351	29 May 2025	Common Stock	65,351	$2.63	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2	All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F3	Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.
F4	Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.